1.
Nakamura, T. & Ichihara, K. N. A. Partial purification and characterization of
hepatocyte growth factor from serum of hepatectomized rats. 122, 10 (1984).
2.
Michalopoulos, G., Houck, K. A., Dolan, M. L. & Luetteke, N. C. Control of
Hepatocyte Replication by Two Serum Factors. 44, 7 (1984).
3.
Nakamura, T. et al. Molecular cloning and expression of human hepatocyte
growth factor. 342, 4 (1989).
4.
Keiji, M. et al. Molecular Cloning and Sequence Analysis of cDNA for Human
Hepatocyte Growth Factor. Biochem. Biophys. Res. Commun. 163, 967–973
(1989).
5.
Weidner, K. M. et al. Evidence for the identity of human scatter factor and human
hepatocyte growth factor. Proc. Natl. Acad. Sci. 88, 7001–7005 (1991).
6.
Trusolino, L., Bertotti, A. & Comoglio, P. M. MET signalling: principles and
functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell
Biol. 11, 834–848 (2010).
7.
Matsumoto, K., Funakoshi, H., Takahashi, H. & Sakai, K. HGF–Met Pathway in
Regeneration and Drug Discovery. Biomedicines 2, 275–300 (2014).
8.
Lokker, N. A. et al. Structure-function analysis of hepatocyte growth factor:
identification of variants that lack mitogenic activity yet retain high affinity
receptor binding. EMBO J. 11, 2503–2510 (1992).
9.
Chirgadze, D. Y. et al. Crystal structure of the NK1 fragment of HGF/SF suggests
a novel mode for growth factor dimerization and receptor binding. Nat. Struct.
Biol. 6, 8 (1999).
10.
Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G. F. Met,
metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915–925 (2003).
11.
Organ, S. L. & Tsao, M.-S. An overview of the c-MET signaling pathway. Ther.
Adv. Med. Oncol. 3, S7–S19 (2011).
107
12.
Lemmon, M. A. & Schlessinger, J. Cell Signaling by Receptor Tyrosine Kinases.
Cell 141, 1117–1134 (2010).
13.
Mele, S. & Johnson, T. K. Receptor Tyrosine Kinases in Development: Insights
from Drosophila. Int. J. Mol. Sci. 21, 188 (2019).
14.
Szilveszter, K. P., Németh, T. & Mócsai, A. Tyrosine Kinases in Autoimmune
and Inflammatory Skin Diseases. Front. Immunol. 10, 1862 (2019).
15.
Wang, H. et al. The Function of the HGF/c-Met Axis in Hepatocellular
Carcinoma. Front. Cell Dev. Biol. 8, 55 (2020).
16.
Thayaparan, T., Spicer, J. F. & Maher, J. The role of the HGF/Met axis in
mesothelioma. Biochem. Soc. Trans. 44, 363–370 (2016).
17.
Cheng, F. & Guo, D. MET in glioma: signaling pathways and targeted therapies.
J. Exp. Clin. Cancer Res. 38, 270 (2019).
18.
Mulcahy, E. Q. X., Colόn, R. R. & Abounader, R. HGF/MET Signaling in
Malignant Brain Tumors. Int. J. Mol. Sci. 21, 7546 (2020).
19.
Miranda, O., Farooqui, M. & Siegfried, J. Status of Agents Targeting the HGF/cMet Axis in Lung Cancer. Cancers 10, 280 (2018).
20.
Moosavi, F., Giovannetti, E., Saso, L. & Firuzi, O. HGF/MET pathway
aberrations as diagnostic, prognostic, and predictive biomarkers in human
cancers. Crit. Rev. Clin. Lab. Sci. 56, 533–566 (2019).
21.
Liang, H. & Wang, M. MET Oncogene in Non-Small Cell Lung Cancer:
Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis.
OncoTargets Ther. Volume 13, 2491–2510 (2020).
22.
Uehara, Y. et al. Placental defect and embryonic lethality in mice lacking
hepatocyte growth factor/scatter factor. Nature 373, 702–705 (1995).
23.
Hammond, D. E. et al. Endosomal Dynamics of Met Determine Signaling Output.
Mol. Biol. Cell 14, 1346–1354 (2003).
24.
Joffre, C. et al. A direct role for Met endocytosis in tumorigenesis. Nat. Cell Biol.
13, 827–837 (2011).
108
25.
Barrow-McGee, R. & Kermorgant, S. Met endosomal signalling: In the right
place, at the right time. Int. J. Biochem. Cell Biol. 49, 69–74 (2014).
26.
Mitchell, A. C., Briquez, P. S., Hubbell, J. A. & Cochran, J. R. Engineering
growth factors for regenerative medicine applications. Acta Biomater. 30, 1–12
(2016).
27.
Wang, Z. et al. Novel biomaterial strategies for controlled growth factor delivery
for biomedical applications. NPG Asia Mater. 9, e435–e435 (2017).
28.
Ross, J. et al. Protein Engineered Variants of Hepatocyte Growth Factor/Scatter
Factor Promote Proliferation of Primary Human Hepatocytes and in Rodent
Liver. Gastroenterology 142, 897–906 (2012).
29.
Ito, K. et al. Artificial human Met agonists based on macrocycle scaffolds. Nat.
Commun. 6, 6373 (2015).
30.
Ueki, R. et al. A chemically unmodified agonistic DNA with growth factor
functionality for in vivo therapeutic application. Sci. Adv. 6, eaay2801 (2020).
31.
Brinkhuis, R. P., Rutjes, F. P. J. T. & van Hest, J. C. M. Polymeric vesicles in
biomedical applications. Polym. Chem. 2, 1449 (2011).
32.
Elsabahy, M. & Wooley, K. L. Design of polymeric nanoparticles for biomedical
delivery applications. Chem. Soc. Rev. 41, 2545 (2012).
33.
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F. & Farokhzad, O.
C. Targeted polymeric therapeutic nanoparticles: design, development and
clinical translation. Chem. Soc. Rev. 41, 2971 (2012).
34.
Zasadzinski, J. A., Wong, B., Forbes, N., Braun, G. & Wu, G. Novel methods of
enhanced retention in and rapid, targeted release from liposomes. Curr. Opin.
Colloid Interface Sci. 16, 203–214 (2011).
35.
Chandrawati, R. & Caruso, F. Biomimetic Liposome- and Polymersome-Based
Multicompartmentalized Assemblies. Langmuir 28, 13798–13807 (2012).
36.
Akbarzadeh, A. et al. Liposome: classification, preparation, and applications.
Nanoscale Res. Lett. 8, 102 (2013).
109
37.
Kumar, S. & Randhawa, J. K. High melting lipid based approach for drug
delivery: Solid lipid nanoparticles. Mater. Sci. Eng. C 33, 1842–1852 (2013).
38.
Kumar, A., Zhang, X. & Liang, X.-J. Gold nanoparticles: Emerging paradigm for
targeted drug delivery system. Biotechnol. Adv. 31, 593–606 (2013).
39.
Wang, S., Wen, Y., Cui, Z. & Xue, Y. Size dependence of adsorption kinetics of
nano-MgO: a theoretical and experimental study. J. Nanoparticle Res. 18, 15
(2016).
40.
Valizadeh, A. et al. Quantum dots: synthesis, bioapplications, and toxicity.
Nanoscale Res. Lett. 7, 480 (2012).
41.
Probst, C. E., Zrazhevskiy, P., Bagalkot, V. & Gao, X. Quantum dots as a
platform for nanoparticle drug delivery vehicle design. Adv. Drug Deliv. Rev. 65,
703–718 (2013).
42.
Speir, J. A., Munshi, S., Wang, G., Baker, T. S. & Johnson, J. E. Structures of the
native and swollen forms of cowpea chlorotic mottle virus determined by X-ray
crystallography and cryo- electron microscopy. 33 (2014).
43.
Gillitzer, E., Suci, P., Young, M. & Douglas, T. Controlled Ligand Display on a
Symmetrical Protein-Cage Architecture Through Mixed Assembly. Small 2, 962–
966 (2006).
44.
Suci, P. A., Varpness, Z., Gillitzer, E., Douglas, T. & Young, M. Targeting and
Photodynamic Killing of a Microbial Pathogen Using Protein Cage Architectures
Functionalized with a Photosensitizer. Langmuir 23, 12280–12286 (2007).
45.
Minten, I. J., Hendriks, L. J. A., Nolte, R. J. M. & Cornelissen, J. J. L. M.
Controlled Encapsulation of Multiple Proteins in Virus Capsids. J. Am. Chem.
Soc. 131, 17771–17773 (2009).
46.
Lin, T. et al. The Refined Crystal Structure of Cowpea Mosaic Virus at 2.8 Å
Resolution. Virology 265, 20–34 (1999).
47.
Ochoa, W. F., Chatterji, A., Lin, T. & Johnson, J. E. Generation and Structural
Analysis of Reactive Empty Particles Derived from an Icosahedral Virus. Chem.
110
Biol. 13, 771–778 (2006).
48.
Steinmetz, N. F., Lomonossoff, G. P. & Evans, D. J. Cowpea Mosaic Virus for
Material Fabrication: Addressable Carboxylate Groups on a Programmable
Nanoscaffold. Langmuir 22, 3488–3490 (2006).
49.
Strable, E. et al. Unnatural Amino Acid Incorporation into Virus-Like Particles.
Bioconjug. Chem. 19, 866–875 (2008).
50.
Golmohammadi, R., Fridborg, K., Bundule, M., Valegård, K. & Liljas, L. The
crystal structure of bacteriophage Qβ at 3.5 Å resolution. Structure 4, 543–554
(1996).
51.
Prasuhn, D. E. et al. Plasma Clearance of Bacteriophage Qβ Particles as a
Function of Surface Charge. J. Am. Chem. Soc. 130, 1328–1334 (2008).
52.
Banerjee, D., Liu, A. P., Voss, N. R., Schmid, S. L. & Finn, M. G. Multivalent
Display and Receptor-Mediated Endocytosis of Transferrin on Virus-Like
Particles. ChemBioChem 11, 1273–1279 (2010).
53.
Uchida, M. et al. Targeting of Cancer Cells with Ferrimagnetic Ferritin Cage
Nanoparticles. J. Am. Chem. Soc. 128, 16626–16633 (2006).
54.
Lin, X. et al. Chimeric Ferritin Nanocages for Multiple Function Loading and
Multimodal Imaging. Nano Lett. 11, 814–819 (2011).
55.
Li, X. et al. Epidermal Growth Factor-Ferritin H-Chain Protein Nanoparticles for
Tumor Active Targeting. Small 8, 2505–2514 (2012).
56.
Zhen, Z. et al. RGD-Modified Apoferritin Nanoparticles for Efficient Drug
Delivery to Tumors. ACS Nano 7, 4830–4837 (2013).
57.
Khoshnejad, M., Parhiz, H., Shuvaev, V. V., Dmochowski, I. J. & Muzykantov,
V. R. Ferritin-based drug delivery systems: Hybrid nanocarriers for vascular
immunotargeting. J. Controlled Release 282, 13–24 (2018).
58.
He, J., Fan, K. & Yan, X. Ferritin drug carrier (FDC) for tumor targeting therapy.
J. Controlled Release 311–312, 288–300 (2019).
59.
Flenniken, M. L. et al. Selective attachment and release of a chemotherapeutic
111
agent from the interior of a protein cage architecture. Chem. Commun. 447 (2005)
doi:10.1039/b413435d.
60.
Guan, X., Chang, Y., Sun, J., Song, J. & Xie, Y. Engineered Hsp Protein
Nanocages for siRNA Delivery. Macromol. Biosci. 18, 1800013 (2018).
61.
Wagner, H. J., Capitain, C. C., Richter, K., Nessling, M. & Mampel, J.
Engineering bacterial microcompartments with heterologous enzyme cargos. Eng.
Life Sci. 17, 36–46 (2017).
62.
Rurup, W. F., Snijder, J., Koay, M. S. T., Heck, A. J. R. & Cornelissen, J. J. L. M.
Self-Sorting of Foreign Proteins in a Bacterial Nanocompartment. J. Am. Chem.
Soc. 136, 3828–3832 (2014).
63.
Moon, H., Lee, J., Min, J. & Kang, S. Developing Genetically Engineered
Encapsulin Protein Cage Nanoparticles as a Targeted Delivery Nanoplatform.
Biomacromolecules 15, 3794–3801 (2014).
64.
Seebeck, F. P., Woycechowsky, K. J., Zhuang, W., Rabe, J. P. & Hilvert, D. A
Simple Tagging System for Protein Encapsulation. J. Am. Chem. Soc. 128, 4516–
4517 (2006).
65.
Gabashvili, A. N. et al. Encapsulins—Bacterial Protein Nanocompartments:
Structure, Properties, and Application. Biomolecules 10, 966 (2020).
66.
Erlendsson, S. et al. Structures of virus-like capsids formed by the Drosophila
neuronal Arc proteins. Nat. Neurosci. 23, 172–175 (2020).
67.
Han, X. & Woycechowsky, K. J. Encapsulation and Controlled Release of Protein
Guests by the Bacillus subtilis Lumazine Synthase Capsid. Biochemistry 56,
6211–6220 (2017).
68.
Azuma, Y., Zschoche, R. & Hilvert, D. The C-terminal peptide of Aquifex
aeolicus riboflavin synthase directs encapsulation of native and foreign guests by
a cage-forming lumazine synthase. J. Biol. Chem. 292, 10321–10327 (2017).
69.
Lilavivat, S., Sardar, D., Jana, S., Thomas, G. C. & Woycechowsky, K. J. In Vivo
Encapsulation of Nucleic Acids Using an Engineered Nonviral Protein Capsid. J.
112
Am. Chem. Soc. 134, 13152–13155 (2012).
70.
Azuma, Y., Edwardson, T. G. W., Terasaka, N. & Hilvert, D. Modular Protein
Cages for Size-Selective RNA Packaging in Vivo. J. Am. Chem. Soc. 140, 566–
569 (2018).
71.
Zhang, X., Meining, W., Fischer, M., Bacher, A. & Ladenstein, R. X-ray structure
analysis and crystallographic refinement of lumazine synthase from the
hyperthermophile Aquifex aeolicus at 1.6 Å resolution: determinants of
thermostability revealed from structural comparisons. J. Mol. Biol. 306, 1099–
1114 (2001).
72.
Min, J., Kim, S., Lee, J. & Kang, S. Lumazine synthase protein cage
nanoparticles as modular delivery platforms for targeted drug delivery. RSC Adv
4, 48596–48600 (2014).
73.
Kim, H., Kang, Y. J., Min, J., Choi, H. & Kang, S. Development of an antibodybinding modular nanoplatform for antibody-guided targeted cell imaging and
delivery. RSC Adv. 6, 19208–19213 (2016).
74.
Wörsdörfer, B., Pianowski, Z. & Hilvert, D. Efficient in Vitro Encapsulation of
Protein Cargo by an Engineered Protein Container. J. Am. Chem. Soc. 134, 909–
911 (2012).
75.
Terasaka, N., Azuma, Y. & Hilvert, D. Laboratory evolution of virus-like
nucleocapsids from nonviral protein cages. Proc. Natl. Acad. Sci. 115, 5432–5437
(2018).
76.
Worsdorfer, B., Woycechowsky, K. J. & Hilvert, D. Directed Evolution of a
Protein Container. Science 331, 589–592 (2011).
77.
Sasaki, E. et al. Structure and assembly of scalable porous protein cages. Nat.
Commun. 8, 14663 (2017).
78.
Tanaka, Y. et al. Structural basis for the drug extrusion mechanism by a MATE
multidrug transporter. Nature 496, 247–251 (2013).
79.
Kodan, A. et al. Structural basis for gating mechanisms of a eukaryotic P113
glycoprotein homolog. Proc. Natl. Acad. Sci. 111, 4049–4054 (2014).
80.
Matsunaga, Y., Bashiruddin, N. K., Kitago, Y., Takagi, J. & Suga, H. Allosteric
Inhibition of a Semaphorin 4D Receptor Plexin B1 by a High-Affinity
Macrocyclic Peptide. Cell Chem. Biol. 23, 1341–1350 (2016).
81.
Morimoto, J., Hayashi, Y. & Suga, H. Discovery of Macrocyclic Peptides Armed
with a Mechanism-Based Warhead: Isoform-Selective Inhibition of Human
Deacetylase SIRT2. Angew. Chem. Int. Ed. 51, 3423–3427 (2012).
82.
Kawamura, A. et al. Highly selective inhibition of histone demethylases by de
novo macrocyclic peptides. Nat. Commun. 8, 14773 (2017).
83.
Yamagishi, Y. Natural Product-Like Macrocyclic N-Methyl-Peptide Inhibitors
against a Ubiquitin Ligase Uncovered from a Ribosome-Expressed De Novo
Library. 18, 1562–1570 (2011).
84.
Hayashi, Y., Morimoto, J. & Suga, H. In Vitro Selection of Anti-Akt2 ThioetherMacrocyclic Peptides Leading to Isoform-Selective Inhibitors. ACS Chem. Biol.
7, 607–613 (2012).
85.
Yu, H. et al. Macrocycle peptides delineate locked-open inhibition mechanism for
microorganism phosphoglycerate mutases. Nat. Commun. 8, 14932 (2017).
86.
Jongkees, S. A. K. Rapid Discovery of Potent and Selective GlycosidaseInhibiting De Novo Peptides. Cell Chem. Biol. 24, 381–390 (2017).
87.
Goto, Y. et al. Reprogramming the Translation Initiation for the Synthesis of
Physiologically Stable Cyclic Peptides. 3, 120–129 (2008).
88.
Vinogradov, A. A., Yin, Y. & Suga, H. Macrocyclic Peptides as Drug
Candidates: Recent Progress and Remaining Challenges. J. Am. Chem. Soc. 141,
4167–4181 (2019).
89.
Mihara, E. et al. Lasso-grafting of macrocyclic peptide pharmacophores yields
multi-functional proteins. https://www.researchsquare.com/article/rs-85705/v1
(2020) doi:10.21203/rs.3.rs-85705/v1.
90.
Azuma, Y., Herger, M. & Hilvert, D. Diversification of Protein Cage Structure
114
Using Circularly Permuted Subunits. J. Am. Chem. Soc. 140, 558–561 (2018).
91.
Fujii, Y. et al. PA tag: A versatile protein tagging system using a super high
affinity antibody against a dodecapeptide derived from human podoplanin.
Protein Expr. Purif. 95, 240–247 (2014).
92.
Mazzone, M. et al. An uncleavable form of pro–scatter factor suppresses tumor
growth and dissemination in mice. J. Clin. Invest. 114, 1418–1432 (2004).
93.
Gherardi, E. et al. Structural basis of hepatocyte growth factor/scatter factor and
MET signalling. Proc. Natl. Acad. Sci. 103, 4046–4051 (2006).
94.
Miao, W. et al. Impaired ligand‐dependent MET activation caused by an
extracellular SEMA domain missense mutation in lung cancer. Cancer Sci. 110,
3340–3349 (2019).
95.
Eklund, H. et al. Three-dimensional structure of horse liver alcohol
dehydrogenase at 2.4 Å resolution. J. Mol. Biol. 102, 27–59 (1976).
96.
Eklund, H. et al. Structure of a triclinic ternary complex of horse liver alcohol
dehydrogenase at 2.9 Å resolution. J. Mol. Biol. 146, 561–587 (1981).
97.
Eklund, H. et al. Three-dimensional structure of horse liver alcohol
dehydrogenase at 2.4 Å resolution. J. Mol. Biol. 102, 27–59 (1976).
98.
Eklund, H. et al. Structure of a triclinic ternary complex of horse liver alcohol
dehydrogenase at 2.9 Å resolution. J. Mol. Biol. 146, 561–587 (1981).
99.
Akagawa, K., Fujiwara, T., Sakamoto, S. & Kudo, K. One-pot sequential alcohol
oxidation and asymmetric α-oxyamination in aqueous media using recyclable
resin-supported peptide catalyst. Chem. Commun. 46, 8040 (2010).
100. Raj, S. B., Ramaswamy, S. & Plapp, B. V. Yeast Alcohol Dehydrogenase
Structure and Catalysis. Biochemistry 53, 5791–5803 (2014).
101. James P., F., Aubrey R., H. J., Rihe, L. & Leslie E., O. Synthesis of long prebiotic
oligomers on mineral surfaces. Nature 381, 59–61 (1996).
102. Benner, S. A., Ellington, A. D. & Tauer, A. Modern metabolism as a palimpsest
of the RNA world. Proc. Natl. Acad. Sci. 86, 7054–7058 (1989).
115
103. Bernhardt, H. S. The RNA world hypothesis: the worst theory of the early
evolution of life (except for all the others)a. Biol. Direct 7, 23 (2012).
104. Takatsuji, R. et al. Ribosomal Synthesis of Backbone-Cyclic Peptides Compatible
with In Vitro Display. J. Am. Chem. Soc. 141, 2279–2287 (2019).
105. Ryota, Y.
In Vitro Selection
of Peptide Catalysts with Alcohol Dehydrogenase
Activity. Master Thesis (2014).
106. Doak, B. C., Zheng, J., Dobritzsch, D. & Kihlberg, J. How Beyond Rule of 5
Drugs and Clinical Candidates Bind to Their Targets. J. Med. Chem. 59, 2312–
2327 (2016).
107. Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future
directions. Drug Discov. Today 20, 122–128 (2015).
108. Rüegger, A. et al. Cyclosporin A, ein immunsuppressiv wirksamer
Peptidmetabolit aus Trichoderma polysporum (L INK ex P ERS .) Rifai. Helv.
Chim. Acta 59, 1075–1092 (1976).
109. Wenger, R. M. Synthesis of Cyclosporine and Analogues: Structural
Requirements for Immunosuppressive Activity. Angew. Chem. Int. Ed. Engl. 24,
77–85 (1985).
110. Liu, J. et al. Calcineurin is a common target of cyclophilin-cyclosporin A and
FKBP-FK506 complexes. Cell 66, 807–815 (1991).
111. Liu, J. et al. Inhibition of T cell signaling by immunophilin-ligand complexes
correlates with loss of calcineurin phosphatase activity. Biochemistry 31, 3896–
3901 (1992).
112. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settingsq. Adv. Drug Deliv. Rev. 24 (2001).
113. Refsgaard, H. H. F. et al. In Silico Prediction of Membrane Permeability from
Calculated Molecular Parameters. J. Med. Chem. 48, 805–811 (2005).
114. Ekins, S. & Rose, J. In silico ADME/Tox: the state of the art. J. Mol. Graph.
116
Model. 20, 305–309 (2002).
115. Ekins, S. et al. Progress in predicting human ADME parameters in silico. J.
Pharmacol. Toxicol. Methods 44, 251–272 (2000).
116. Ekins, S. et al. Three-Dimensional Quantitative Structure-Permeability
Relationship Analysis for a Series of Inhibitors of Rhinovirus Replication. J.
Chem. Inf. Comput. Sci. 41, 1578–1586 (2001).
117. Mälkiä, A., Murtomäki, L., Urtti, A. & Kontturi, K. Drug permeation in
biomembranes. Eur. J. Pharm. Sci. 23, 13–47 (2004).
118. Fujikawa, M., Ano, R., Nakao, K., Shimizu, R. & Akamatsu, M. Relationships
between structure and high-throughput screening permeability of diverse drugs
with artificial membranes: Application to prediction of Caco-2 cell permeability.
Bioorg. Med. Chem. 13, 4721–4732 (2005).
119. Veber, D. F. et al. Molecular Properties That Influence the Oral Bioavailability of
Drug Candidates. J. Med. Chem. 45, 2615–2623 (2002).
120. Leung, S. S. F., Mijalkovic, J., Borrelli, K. & Jacobson, M. P. Testing Physical
Models of Passive Membrane Permeation. J. Chem. Inf. Model. 52, 1621–1636
(2012).
121. Witek, J. et al. Kinetic Models of Cyclosporin A in Polar and Apolar
Environments Reveal Multiple Congruent Conformational States. J. Chem. Inf.
Model. 56, 1547–1562 (2016).
122. Rezai, T. et al. Conformational Flexibility, Internal Hydrogen Bonding, and
Passive Membrane Permeability: Successful in Silico Prediction of the Relative
Permeabilities of Cyclic Peptides. J. Am. Chem. Soc. 128, 14073–14080 (2006).
123. Witek, J. et al. Rationalization of the Membrane Permeability Differences in a
Series of Analogue Cyclic Decapeptides. J. Chem. Inf. Model. 59, 294–308
(2019).
124. Poger, D., Van Gunsteren, W. F. & Mark, A. E. A new force field for simulating
phosphatidylcholine bilayers. J. Comput. Chem. 31, 1117–1125 (2010).
117
125. Nathan, S. et al. Definition and testing of the GROMOS force-field versions
54A7 and 54B7. Eur Biophys J 40, 843–856 (2011).
126. Hritz, J. & Oostenbrink, C. Hamiltonian replica exchange molecular dynamics
using soft-core interactions. J. Chem. Phys. 128, 144121 (2008).
127. Meli, M. & Colombo, G. A Hamiltonian Replica Exchange Molecular Dynamics
(MD) Method for the Study of Folding, Based on the Analysis of the Stabilization
Determinants of Proteins. Int J Mol Sci 13 (2013).
118
List of accomplishments
【Publication related to the thesis】
1. “In vitro selection of an alcohol dehydrogenase peptidic enzyme”, Yamato
Komatsu, Ryota Yokosuka, Yuki Goto, Hiroaki Suga, Peptide Science, 2020,
99-100
【Publications not related to the thesis】
1. “Ribosomal Synthesis of Backbone-Cyclic Peptides Compatible with In Vitro
Display”, Ryo Takatsuji, Koki Shinbara, Takayuki Katoh, Yuki Goto, Toby
Passioura, Ryo Yajima, Yamato Komatsu, and Hiroaki Suga, J. Am. Chem. Soc.,
2019, 141, 2279-2287
2. ⼩松 ⼤和, 後藤 佑樹, 菅 裕明 「擬天然ペプチドの試験管内⼈⼯⽣
合成系による合成技術及びその医薬品候補分⼦探索への応⽤」,『第 80
号酵素⼯学研究会トピックス』, 酵素⼯学研究会, p23-28 (2018)
【Poster presentations】
1. “タンパク質酵素の起源に迫る!?アルコール酸化活性を持つペプチド
酵素のスクリーニング系構築”, ⼩松 ⼤和, 後藤 祐樹, 菅 裕明, 若⼿
ペプチド夏の勉強会, ⻑崎, 2017 年 8 ⽉
2. “アルコール脱⽔素触媒活性を有する短鎖ペプチド酵素の試験管内セ
レクション”, ⼩松 ⼤和, 横須賀 亮太, 後藤 祐樹, 菅 裕明, ⽇本ケミ
カルバイオロジー学会（JSCB）第 13 回年会, 東京, 2018 年 6 ⽉
3. “In vitro selection of an alcohol dehydrogenase peptidic enzyme”, Yamato
Komatsu, Ryota Yokosuka, Yuki Goto, Hiroaki Suga, 第 56 回ペプチド討論
会, 東京, 2019 年, 10 ⽉
119
Acknowledgements
This thesis was completed under the supervision of Prof. Hiroaki Suga. I would like
to express my sincere gratitude to Prof. Suga for his kind guidance, valuable suggestions
and encouragement throughout this work. I would like to thank Asst. Prof. Naohiro
Terasaka and Assoc. Prof. Yuki Goto for valuable discussions and teaching me various
concepts and techniques for organic chemistry and biochemistry. I also thank Assoc. Prof.
Takayuki Kato, Assoc. Prof. Naokazu Kano and Asst. Prof. Toby Passioura for their
helpful advice and discussions. I thank all members in Suga Lab.
I appreciate the work done by Prof. Kunio Matsumoto’s group in Kanazawa
University for biological assays in chapter 2 and 3. I also really thank Prof. Riniker
Sereina’s group, especially Prof. Riniker Sereina and Dr. König Gerhard, for the usage
authorization and lecture of GROMOS software in chapter 5.
I thank Materials Education program for the future leaders in Research, Insudtry, and
Technology (MERIT) for financial support. I also thank Japan Society for the Promotion
of Science (JSPS) for a grant and financial support.
Finally, I would like to thank my family for invaluable assistance and cheering words.
120
...
論文の公開元へ
